^
Association details:
Biomarker:PD-L1 underexpression
Cancer:Melanoma
Drug:Yervoy (ipilimumab) (CTLA4 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
07/12/2011
Excerpt:
Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression.